3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
16
Neoplasms
4
Neoplasm Metastasis
4
Prostatic Neoplasms
3
Multiple Myeloma
3
Giant Cell Tumor of Bone
3
Carcinoma, Renal Cell
3
Smoldering Multiple Myeloma
2
Recurrence
2
Osteoporosis
2
Melanoma
2
Kidney Neoplasms
2
Bone Cysts, Aneurysmal
2
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Cancer Metastatic
1
Parathyroid Neoplasms
1
Osteoporotic Fractures
1
Osteopetrosis, mild autosomal recessive form
1
Osteopetrosis, Autosomal Recessive 7
1
Osteoblastoma
1
Neoplastic Cells, Circulating
1
Musculoskeletal Pain
1
Mastocytosis, Systemic
1
Lung Neoplasms
1
Inflammatory Breast Neoplasms
1
Hyperparathyroidism, Primary
1
Granuloma, Giant Cell
1
Giant Cell Tumors
1
Interventions
Cyclophosphamide
23
Paclitaxel
19
Epirubicin
14
Doxorubicin
13
Carboplatin
13
Trastuzumab
12
Docetaxel
10
Taxes
9
Albumin-Bound Paclitaxel
7
pembrolizumab
5
Radiotherapy
5
Fluorouracil
5
Filgrastim
5
Bevacizumab
5
130-nm albumin-bound paclitaxel
5
pertuzumab
4
Neoadjuvant Therapy
4
Cisplatin
4
eribulin
3
Thiotepa
3
Tamoxifen
3
Panitumumab
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Flow Cytometry
3
Capecitabine
3
Biopsy
3
sargramostim
2
Specimen Handling
2
Peripheral Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Inflammatory Breast Neoplasms
×
Denosumab
×
Clear all
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled